Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2A1 | Q16548 | 4/20 | 0.58 |
| ▸ | BID | P55957 | 3/20 | 0.58 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.58 |
| ▸ | BCL2 | P10415 | 16/20 | 0.54 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.50 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31450616 | 1.00 | BCL2A1 (0.58) | BCL2A1BIDMCL1BCL2BCL2L1 | |
| SCHEMBL31450861 | 0.94 | BCL2 (0.54) | BCL2A1BIDMCL1BCL2BCL2L1 | |
| SCHEMBL26648210 | 0.94 | BCL2 (0.54) | BCL2A1BIDMCL1BCL2BCL2L1 | |
| SCHEMBL31450744 | 0.86 | BCL2A1 (0.63) | BCL2A1BIDMCL1BCL2BCL2L1 | |
| SCHEMBL1701594 | 0.86 | BCL2A1 (0.63) | BCL2A1BIDMCL1BCL2BCL2L1 | |
| SCHEMBL26647789 | 0.86 | BCL2A1 (0.51) | BCL2A1BIDMCL1BCL2BCL2L1 | |
| SCHEMBL31450986 | 0.86 | BCL2A1 (0.51) | BCL2A1BIDMCL1BCL2BCL2L1 | |
| SCHEMBL26648052 | 0.86 | BCL2A1 (0.51) | BCL2A1BIDMCL1BCL2BCL2L1 | |
| SCHEMBL19692632 | 0.86 | BCL2 (0.54) | BCL2A1BIDMCL1BCL2BCL2L1 | |
| SCHEMBL31344650 | 0.86 | BCL2 (0.59) | BCL2A1BIDMCL1BCL2BCL2L1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092057-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-02 | — | — | US | disclosed |
| WO-2023220425-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023220425-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260092057-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | BCL2L2, BCL2A1, BCL2L1 | BCL2A1 2/4885BID 17/4885MCL1 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.